HealthCare Global Enterprises Ltd. (HCG) AI Stock Analysis

• Market Cap: ₹93.53B
• Dividend Yield: N/A
• Average Volume (3M): 13.20K
• Price to Earnings (P/E): 252.0
• Beta (1Y): 0.38
• Revenue Growth: 16.85%
• EPS Growth: -29.52%
• Country: IN
• Employees: 6,150
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Care Facilities
• EPS (TTM): 0.36
• Shares Outstanding: 139,415,370
• 10 Day Avg. Volume: 17,295
• 30 Day Avg. Volume: 13,197
• PEG Ratio: -21.26
• Price to Book (P/B): 7.99
• Price to Sales (P/S): 3.32
• P/FCF Ratio: 68.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹621.50
• Price Target Upside: -8.80% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 61 Neutral
• Price Target: ₹653.00 ▼(-4.17% Downside)

The stock score is primarily driven by strong financial performance, characterized by revenue growth and profitability improvements. However, overvaluation concerns and technical indicators suggesting overbought conditions pose significant risks, balancing the overall score to a moderate level.

HealthCare Global Enterprises Ltd. Business Overview & Revenue Model

Company Description

HealthCare Global Enterprises Ltd. (HCG) is a leading provider of specialized cancer care in India, operating a network of comprehensive cancer centers. The company focuses on delivering advanced cancer diagnostics and treatment services, offering a wide range of oncology services including medical oncology, surgical oncology, and radiation oncology. HCG is also involved in research and development in the field of cancer care, aiming to improve patient outcomes through innovative therapies and technologies.

How the Company Makes Money

HCG generates revenue primarily through the provision of medical services related to cancer treatment. Its key revenue streams include patient fees for consultations, diagnostics, and treatment procedures encompassing chemotherapy, radiation therapy, and surgery. The company also earns income from its laboratory services and imaging centers. Additionally, HCG benefits from partnerships and collaborations with pharmaceutical companies and research institutions, which contribute to its research and development initiatives and provide further revenue opportunities. The company's strategic expansion into tier 2 and tier 3 cities in India helps in increasing its patient base and enhancing its revenue potential.

HealthCare Global Enterprises Ltd. Financial Statement Overview

Summary

HealthCare Global Enterprises Ltd. has demonstrated strong revenue growth and improving profitability margins. However, the company faces challenges with decreasing net income and a leveraged balance sheet, indicating potential financial stability risks.

Income Statement

HealthCare Global Enterprises Ltd. has shown a strong revenue growth trajectory over the years. The company improved its revenue by 17.35% from 2024 to 2025. The gross profit margin stands at 52.11% and net profit margin at 2.00% for 2025, with a noticeable improvement in profitability metrics like EBIT and EBITDA margins, which are at 7.93% and 19.06% respectively. However, the net income has decreased compared to 2024, indicating potential operational challenges.

Balance Sheet

The company shows a moderately balanced financial structure with a debt-to-equity ratio of 1.99, indicating reliance on debt. The equity ratio at 26.02% reflects a reasonable level of equity financing. Return on Equity is low at 4.81%, suggesting limited profitability for equity holders. Overall, the balance sheet indicates a stable but leveraged position.

Cash Flow

HealthCare Global Enterprises Ltd. has demonstrated consistent positive operating cash flows, showing operational efficiency. The Operating Cash Flow to Net Income ratio is robust at 7.14, indicating strong cash flow generation relative to net income. Free Cash Flow has shown a growth of 9.39% from the previous year, reflecting healthy cash management. However, the Free Cash Flow to Net Income ratio at 2.44 highlights potential concerns in cash flow efficiency.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	22.18B	22.18B	18.90B	16.76B	13.83B	10.04B
Gross Profit	10.24B	11.56B	9.80B	3.52B	7.01B	5.04B
EBITDA	4.22B	4.23B	3.50B	3.06B	3.41B	474.52M
Net Income	444.10M	444.10M	481.55M	293.49M	537.33M	-1.93B
Balance Sheet
Total Assets	35.43B	35.43B	27.07B	23.16B	22.20B	20.36B
Cash, Cash Equivalents and Short-Term Investments	3.53B	3.53B	3.03B	1.97B	2.04B	1.66B
Total Debt	18.37B	18.37B	12.74B	9.01B	9.15B	9.78B
Total Liabilities	25.53B	25.53B	18.42B	14.47B	13.36B	13.22B
Stockholders Equity	9.22B	9.22B	8.26B	8.61B	8.70B	6.97B
Cash Flow
Free Cash Flow	0.00	1.08B	988.99M	1.18B	1.49B	850.97M
Operating Cash Flow	0.00	3.17B	2.85B	2.52B	2.20B	1.21B
Investing Cash Flow	0.00	-4.88B	-2.26B	-1.33B	1.25B	-1.71B
Financing Cash Flow	0.00	-424.40M	-640.16M	-1.40B	-1.55B	1.12B

HealthCare Global Enterprises Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 681.45
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HCG, the sentiment is Positive. The current price of 681.45 is above the 20-day moving average (MA) of 592.86, above the 50-day MA of 565.19, and above the 200-day MA of 526.08, indicating a bullish trend. The MACD of 19.15 indicates Negative momentum. The RSI at 76.92 is Negative, neither overbought nor oversold. The STOCH value of 77.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:HCG.

HealthCare Global Enterprises Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASTERDM	77 Outperform	₹312.56B	95.11		20.22%	-53.19%	-94.01%
FORTIS	75 Outperform	₹703.28B	80.97		0.11%	14.04%	32.99%
MEDANTA	75 Outperform	₹370.71B	69.39		―	15.42%	10.64%
MAXHEALTH	71 Outperform	₹1.23T	114.02		0.12%	32.65%	8.86%
NH	68 Neutral	₹370.31B	46.93		0.25%	12.09%	-2.79%
HCG	61 Neutral	₹93.53B	252.00		―	16.85%	-29.52%
Sector *	51 Neutral	kr6.00B	8.78	-28.70%	2.24%	51.61%	19.20%